Stock Ratings / Health Care / GRAL / earnings

BLLN (71) OSCR (53) CON (68) HSIC (59) ⌘ Pro Terminal →

GRAIL Inc. (GRAL) Next Earnings Date & Expected ±12.5% Move

$158.92 +0.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

GRAIL Inc. (GRAL) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $7.10B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRAL)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$19.86 Expected Swing

MODEL EARNINGS SETUP GAUGE

GRAL Quantitative Pre-Earnings Setup: 54/100

Trailing EPS: $-9.14 • YoY Revenue Growth: 17.2%

Model Bullish Setup (54/100)Model Risk Weight (46/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$147.2M	-$408.4M	-$299.9M	52%
FY 2024	2024-12-31	$125.6M	-$2.03B	-$582.4M	52%
FY 2023	2023-12-31	$93.1M	-$1.47B	-$600.0M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRAL)

✓Walkthrough of GRAL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GRAL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +185.52%▲ ASCENDING CHANNEL

2026-11-01O $157.9H $158.9L $157.9C $158.9VOL 761.5K

RES: $185.1SUP: $90.56SMA50: $113.6SMA200: $78.37

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRAL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRAL Butterfly Map → + Track GRAL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

15.7%/yr Implied 5Y Growth

vs. +17.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GRAL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRAL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GRAL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRAL)

Health Care Rank #133 of 188 ⚔️ BLLN vs GRAL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GRAL vs. BLLN, OSCR, CON, HSIC)

Industry: Medical Specialities (20 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, GRAIL Inc. (GRAL) ranks #133 by composite RQD confidence (54/100, grade D+) and #135 by equity capitalization ($7.10B). Within this direct 5-issuer industry benchmark cohort, HSIC leads on earnings valuation at 23.0x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and — gross margin. BLLN currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with GRAL at 54/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GRAL ACTIVE GRAIL Inc.	D+	54/100	—	—	-18.0%	+0.66%	$7.10B	Benchmark Subject
BLLN BillionToOne Inc.	B-	71/100	—	68.3%	2.9%	+0.74%	$5.42B	/blln-vs-gral →
OSCR Oscar Health Inc.	D+	53/100	—	—	-35.0%	+1.02%	$9.50B	/oscr-vs-gral →
CON Concentra Group Holdings Parent Inc.	C+	68/100	31.6x	—	19.7%	+1.63%	$5.26B	/con-vs-gral →
HSIC Henry Schein Inc.	C-	59/100	23.0x	31.1%	11.2%	+1.74%	$9.63B	/hsic-vs-gral →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001699031

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GRAIL Inc. (GRAL) reported GAAP revenue of $147.2M (+17.2% vs. FY2024 revenue of $125.6M , and +58.1% cumulative change since FY2023) , GAAP net income of -$408.4M, operating cash flow of -$299.0M, and free cash flow of -$299.9M (+48.5% YoY). On the balance sheet, GRAL closed FY2025 with $2.92B in total assets against $154.9M in total debt (Altman Z-Score: 7.26, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$147.2M	-$408.4M	-$299.0M	-$299.9M	$2.92B	$154.9M
FY2024 (FY)	2024-12-31	$125.6M	-$2.03B	-$577.2M	-$582.4M	$2.98B	$216.0M
FY2023 (FY)	2023-12-31	$93.1M	-$1.47B	-$595.8M	-$600.0M	$3.90B	$913.6M

3. GRAL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRAL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, GRAIL Inc. (NASDAQ: GRAL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $158.92 (+0.66% 1D, market cap $7.10B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 6/20. Across 188 tracked Health Care issuers, GRAL ranks #133 in composite RQD confidence.

How does GRAL compare to BLLN and OSCR in the Health Care sector?

Within the Health Care sector (Medical Specialities), GRAL carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.0%. By comparison, BLLN (BillionToOne Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC 2.9%, cap $5.42B) and OSCR (Oscar Health Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $9.50B). Among the 5-stock peer group, HSIC leads on earnings multiple (23.0x) while CON leads on capital efficiency (19.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GRAL?

Per GRAL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001699031), GRAIL Inc. generated $147.2M in revenue (+17.2% YoY), -$408.4M in net income, and -$299.9M in free cash flow against $2.92B in total assets and $154.9M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GRAL trading relative to its 50-day, 200-day, and 52-week technical levels?

GRAL last traded at $158.92 (+0.66% on volume of 761,502 shares), positioning the stock +39.92% above its 50-day simple moving average ($113.58) and +102.78% above its 200-day simple moving average ($78.37). Across its 52-week range of $41.50 to $166.48, GRAL sits at the 94.0% percentile with a 14-day RSI of 63.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($139.06 to $178.78).

GRAL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is GRAL's next earnings date?

Based on SEC filing cadence, GRAIL Inc. (GRAL)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is GRAL stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for GRAL, spanning a range between $139.06 and $178.78.

Direct Sub-Reports: GRAL RQD Cockpit GRAL 12M Forecast GRAL Earnings & Move GRAL Dividends & DRIP GRAL Insiders & 13F GRAL Whale Options GRAL Profit Sankey GRAL News & Why